Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Calliditas: Feedback from Novartis Iptacopan challenger

JU

Johan Unnerus

Novartis has a Nephrology pipeline base on Iptacopan, and one target therapy is lgAN. As a result, Iptacopan is one future potential Nefecon challenger. During the ongoing ERA-ERDTA Congress, Novartis presented top-line phase II results based on 112 patients after 90 days.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers